This week, international lung cancer specialists convened in Sinaia, Romania, for the ESMO in Focus – Lung Cancer Romania 2026 conference, aiming to align regional oncology practices with global advances in early detection, biomarker-driven therapies, and equitable access to innovative treatments for non-small cell lung cancer (NSCLC), the predominant form of the disease affecting Romanian patients.
Why This Conference Matters for Romania’s Lung Cancer Burden
Lung cancer remains the leading cause of cancer-related death in Romania, with over 6,000 new cases diagnosed annually and a five-year survival rate below 15%, significantly lagging behind the EU average of 20%. The ESMO in Focus forum directly addresses this gap by bringing together experts from the European Society for Medical Oncology (ESMO) to update Romanian clinicians on practice-changing data from recent phase III trials, including adjuvant osimertinib for EGFR-mutated NSCLC and novel bispecific antibodies targeting MET and HER3 pathways. These discussions are critical as Romania prepares to implement its 2026–2030 National Cancer Control Plan, which prioritizes molecular testing expansion and tele-oncology outreach to underserved regions.
In Plain English: The Clinical Takeaway
- Early detection through low-dose CT screening can reduce lung cancer mortality by up to 20% in high-risk smokers, yet fewer than 5% of eligible Romanians currently access this service.
- Targeted therapies like osimertinib have transformed outcomes for patients with EGFR mutations, but access remains inconsistent outside major urban centers due to reimbursement delays.
- Liquid biopsy blood tests, which detect tumor DNA non-invasively, are now recommended by ESMO for monitoring treatment resistance and may soon replace repeated tissue biopsies in community hospitals.
Bridging Global Evidence to Local Practice: The Osimertinib Advantage
A central theme of the Sinaia discussions was the long-term follow-up of the ADAURA trial (NCT02511106), which demonstrated that adjuvant osimertinib—a third-generation EGFR tyrosine kinase inhibitor (TKI)—significantly prolongs disease-free survival in patients with completely resected stage IB–IIIA EGFR-mutated NSCLC. At five years, 73% of patients receiving osimertinib remained recurrence-free compared to 38% on placebo, a hazard ratio of 0.20 (p<0.001). Osimertinib works by irreversibly blocking mutant EGFR proteins that drive uncontrolled cell growth, while sparing wild-type EGFR in healthy tissues, thereby reducing common TKI side effects like rash and diarrhea.
Despite EMA approval since 2020 and inclusion in Romania’s National Health Insurance Fund (CNAS) reimbursement list, real-world data from the Bucharest Oncology Institute show that only 40% of eligible EGFR-positive patients receive adjuvant osimertinib within 12 weeks of surgery, primarily due to delays in pathologic EGFR testing and prior authorization requirements. Experts at the conference urged streamlining reflex testing algorithms in pathology labs and expanding CNAS coverage for next-generation sequencing (NGS) panels to match ESMO 2024 guidelines.
“Romania has the clinical expertise to deliver precision oncology, but systemic bottlenecks in diagnostics and drug approval are preventing patients from benefiting from proven therapies like osimertinib. We need parity in access—not just in Bucharest, but in Iași, Cluj, and Timișoara.”
Liquid Biopsy and the Shift Toward Dynamic Treatment Monitoring
Another focal point was the clinical utility of circulating tumor DNA (ctDNA) assays, exemplified by the Guardant Reveal™ and Roche cobas® EGFR Mutation Test v2 platforms. These liquid biopsies detect minute fragments of tumor-derived DNA in blood samples, enabling real-time tracking of resistance mutations such as EGFR T790M or MET amplification without invasive re-biopsy. In the phase III FLAURA2 trial (NCT04035486), combining osimertinib with chemotherapy improved median progression-free survival to 25.8 months versus 16.5 months with osimertinib alone in first-line metastatic EGFR-mutated NSCLC, reinforcing the need for dynamic biomarker assessment during treatment.
While liquid biopsy is routinely used in Germany, France, and the UK’s NHS, adoption in Romania remains limited to private oncology centers due to lack of CNAS reimbursement and insufficient training in interpreting variant allele frequency (VAF) thresholds. Conference speakers cited a 2025 pilot study from Cluj-Napoca showing that ctDNA-guided therapy changes improved time-to-treatment-intensification by 3.2 months in 68 patients with relapsed NSCLC, advocating for national pilot integration into regional oncology networks.
Addressing Disparities: Tobacco Control and Screening Access
Beyond therapeutics, the conference emphasized primary prevention, noting that 85% of lung cancer cases in Romania are linked to tobacco employ, with smoking prevalence at 26% among adults—among the highest in the EU. Experts referenced the WHO’s MPOWER framework and urged alignment with the EU’s Tobacco Products Directive, including plain packaging and increased excise taxes, which modeling shows could reduce smoking initiation by 15% over five years.
Regarding screening, the NELSON trial demonstrated that biennial low-dose CT screening in high-risk individuals (ages 50–75 with ≥30 pack-year history) reduces lung cancer mortality by 24% at 10 years. Yet Romania lacks a national organized screening program. Presenters highlighted a successful community-based initiative in Brașov County, where mobile CT units increased screening uptake from 2% to 18% in one year through partnership with family doctors and smoking cessation hotlines—a model proposed for scaling under the 2026 National Cancer Plan.
Contraindications & When to Consult a Doctor
Osimertinib is contraindicated in patients with known hypersensitivity to the drug or severe hepatic impairment (Child-Pugh C). Common side effects include diarrhea (41%), rash (28%), and nail toxicity (19%); interstitial lung disease occurs in <3% but requires prompt discontinuation. Patients on osimertinib should seek immediate care for new dyspnea, fever, or worsening cough, as these may signal pneumonitis. Liquid biopsy is not recommended for initial diagnosis in patients with insufficient tumor shed (e.g., early-stage adenocarcinoma <1 cm) or active clonal hematopoiesis, which can cause false-positive results. Any persistent cough lasting >3 weeks, hemoptysis, or unexplained weight loss warrants urgent medical evaluation, regardless of smoking history.
As Romania advances its oncology infrastructure, conferences like ESMO in Focus serve not only as knowledge conduits but as catalysts for policy change. The convergence of global evidence, local advocacy, and systemic reform offers a tangible path toward narrowing the survival gap—provided that diagnostics, therapeutics, and prevention strategies are implemented with equity and urgency.
References
- ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC. NEJM 2020.
- FLAURA2: Osimertinib Plus Chemotherapy in First-Line Metastatic NSCLC. NEJM 2021.
- Liquid Biopsy for EGFR Mutation Detection in NSCLC. J Thorac Oncol 2022.
- WHO Report on the Global Tobacco Epidemic, 2023.
- NELSON Trial: Low-Dose CT Screening for Lung Cancer. NEJM 2020.
